-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Neutral on Conmed, Lowers Price Target to $58

Benzinga·05/01/2025 17:47:44
Listen to the news
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and lowers the price target from $70 to $58.